Peppy vs. SwissChems: reading the FDA warning letter in context

Disclosure: Peppy Care publishes this comparison of its own service. Public information checked October 22, 2026; no firsthand product testing. Seller statements are attributed, not independently certified.

The FDA warning letter to SwissChems, dated December 10, 2024, identifies swisschems.is. It describes FDA concerns about products including semaglutide and retatrutide being marketed as unapproved new drugs. Readers should consult the letter itself rather than rely on an undated screenshot or a competitor’s summary.

The SwissChems storefront could not be fully accessed during this review. Consequently, this article does not report present inventory, prices, fulfillment performance, or changes made in response to the letter. A blocked page is not evidence that a seller has closed.

FDA’s letter explains its interpretation of the intended uses shown by the website at the time of its review. This is a useful reminder that a research disclaimer should not be read separately from the rest of a product’s marketing. The full context can matter to a regulator’s assessment.

It would be a different claim to say that every product ever sold under the name has the same status. This article does not make that claim. Nor does it infer a final court judgment, a permanent operating ban, or a lack of remediation from the warning letter alone. Those conclusions would require additional, specific evidence.

Peppy’s published process describes review by a licensed provider, with a prescription sent to a licensed compounding pharmacy when treatment is approved. This provides a framework for asking who makes the medical decision and who dispenses. It is not an exemption from product-specific regulatory requirements.

The same scrutiny applies to Peppy’s proposed treatment. FDA’s compounding guidance says compounded medicines are not FDA-approved. Ask whether the exact product is approved or compounded, what supports its use for your condition, and why an available approved option would or would not fit. A competitor’s warning letter cannot establish the safety or effectiveness of a Peppy prescription.

If the goal is medical treatment, begin with the current clinician and pharmacy identities. FDA’s online-pharmacy guidance recommends checking licensing, prescription requirements, and pharmacist access. Verify those facts directly instead of using the presence or absence of a warning letter as the entire evaluation.

For historical claims, record the issuing agency, named domain, publication date, and conduct discussed. For present-day claims, obtain present-day evidence. Our guide to FDA registration and approval explains another common source of confusion. Keeping these categories separate makes a comparison more useful than a simple “approved versus banned” label that the record does not support.